Daily Ards Research Analysis
A neonatal RCT found that using a higher FiO2 threshold (40%) for surfactant in preterm RDS was non-inferior to 30% and reduced surfactant use without added harms. A mechanistic study identified a distinct PD-L1+ neutrophil subpopulation in sepsis-induced ARDS using scRNA-seq and a CLP mouse model. An individualized treatment rule for early steroids in CAP showed only inconsistent benefits versus observed practice.
Summary
A neonatal RCT found that using a higher FiO2 threshold (40%) for surfactant in preterm RDS was non-inferior to 30% and reduced surfactant use without added harms. A mechanistic study identified a distinct PD-L1+ neutrophil subpopulation in sepsis-induced ARDS using scRNA-seq and a CLP mouse model. An individualized treatment rule for early steroids in CAP showed only inconsistent benefits versus observed practice.
Research Themes
- Neonatal respiratory management and surfactant stewardship
- Immunopathology of sepsis-induced ARDS (PD-L1+ neutrophils)
- Precision therapeutics in pneumonia (steroid decision rules)
Selected Articles
1. Higher (40%) versus lower (30%) FiO
In a non-inferiority RCT of 205 preterm infants (26–32 weeks) on CPAP, initiating surfactant at FiO2 40% was non-inferior to 30% for total respiratory support time. The 40% threshold significantly reduced surfactant exposure without increasing BPD, air leaks, hsPDA, mortality, or length of stay.
Impact: This trial directly tests a long-standing guideline threshold and shows a strategy to safely reduce surfactant use and workload. It is the first head-to-head RCT on FiO2 thresholds for surfactant.
Clinical Implications: For preterm infants (26–32 weeks) stabilized on CPAP, clinicians may consider a 40% FiO2 threshold for surfactant to reduce exposure without compromising outcomes, particularly in resource-limited settings.
Key Findings
- A 40% FiO2 threshold was non-inferior to 30% for total duration of respiratory support.
- Use of the 40% threshold significantly reduced surfactant exposure within 6 hours of birth.
- No increase in adverse outcomes (BPD ≥2, air leaks, hsPDA requiring treatment, all-cause mortality, or hospital stay) was observed.
- Subgroup analysis for 26–29 weeks' gestation was conducted.
Methodological Strengths
- Prospective randomized non-inferiority trial with trial registration (CTRI/2023/12/060562).
- Clear primary and secondary outcomes with clinically relevant endpoints.
Limitations
- Modest sample size (N=205) may limit precision for rare adverse events.
- Generalizability limited to CPAP-stabilized infants at 26–32 weeks' gestation.
- Longer-term outcomes beyond hospitalization are not reported in the abstract.
Future Directions: Multicenter RCTs across broader gestational ages and care settings, with long-term respiratory and neurodevelopmental outcomes, to inform guideline updates.
UNLABELLED: The optimal FiO₂ threshold for surfactant administration in preterm neonates with respiratory distress syndrome (RDS) remains uncertain, with limited evidence supporting current guideline recommendations. The objective was to compare the total duration of respiratory support between two FiO₂ thresholds for surfactant administration in preterm neonates stabilized on CPAP. In this non-inferiority randomized control trial (RCT), preterm neonates (26-32 weeks' gestation) with RDS were randomized at 1 h of life to receive surfactant at FiO₂ thresholds of either 40% or 30%. The primary outcome was total duration of respiratory support. The secondary outcomes were requirement of surfactant within 6 h after birth, requirement of repeat dose of surfactant, common morbidities of prematurity bronchopulmonary dysplasia (BPD) stage ≥ 2, air leaks, hemodynamically significant patent ductus arteriosus (hsPDA) (requiring treatment), all-cause mortality, and total duration of hospital stay. Subgroup analysis for gestation between 26 and 29 weeks was done. A total of 205 neonates with a mean birth weight of 1237.92 ± 328.89 g and a mean gestation age of 30.06 ± 1.85 weeks were enrolled. The mean duration of respiratory support was 140.8 h in 40% FiO CONCLUSION: This first randomized controlled trial directly comparing FiO₂ thresholds of 40% versus 30% for surfactant administration in preterm infants (26-32 weeks) found the higher threshold to be non-inferior, with comparable respiratory and clinical outcomes. The use of a 40% threshold significantly reduced surfactant exposure without increasing complications, supporting its role as a safe and cost-effective strategy for resource-limited settings. TRIAL REGISTRATION: CTRI/2023/12/060562. WHAT IS KNOWN: • Early surfactant administration improves outcomes in preterm neonates with RDS. • International guidelines generally recommend a FiO₂ threshold of 30% for surfactant therapy. WHAT IS NEW: • This is the first randomized controlled trial directly comparing FiO₂ thresholds of 40% versus 30% for surfactant administration. • A 40% threshold was non-inferior to 30% in preterm infants (26-32 weeks) without an increase in adverse outcomes, and thus has the potential to support cost effective neonatal care in resource-limited settings and reduce NICU workload. .
2. PD-L1
Using scRNA-seq of septic lungs, the authors identified a distinct PD-L1+ neutrophil subpopulation and isolated these cells in a CLP mouse model. The work highlights PD-L1-associated neutrophil heterogeneity in sepsis-induced lung injury and suggests a potential immunomodulatory target.
Impact: Introduces a mechanistic cell-state target (PD-L1+ neutrophils) in sepsis-induced ARDS using cutting-edge single-cell profiling with in vivo validation.
Clinical Implications: While preclinical, modulating PD-L1+ neutrophils or the PD-1/PD-L1 axis may represent a future therapeutic avenue for sepsis-induced ARDS pending translational validation.
Key Findings
- scRNA-seq identified a distinct PD-L1+ neutrophil subpopulation in septic lungs.
- In a CLP murine sepsis model, PD-L1+ neutrophils were isolated for downstream analyses.
- Findings underscore PD-L1-associated neutrophil heterogeneity in sepsis-induced lung injury.
Methodological Strengths
- Integration of scRNA-seq to resolve neutrophil heterogeneity at single-cell resolution.
- Use of an established in vivo sepsis model (CLP) to isolate target subpopulations.
Limitations
- Preclinical study in a murine model limits direct clinical generalizability.
- Human validation and functional causality are not described in the abstract.
Future Directions: Validate PD-L1+ neutrophil signatures in human sepsis-ARDS cohorts and test therapeutic modulation of the PD-1/PD-L1 axis in translational models.
BACKGROUND: Sepsis-induced acute respiratory distress syndrome (ARDS) is characterized by microvascular dysfunction, uncontrolled inflammation, and pulmonary edema, leading to high morbidity and mortality. Despite their clinical importance, targeted therapies are lacking. Neutrophils play a critical role in sepsis-induced lung injury, but the specific contributions of PD-L1 METHODS: We employed single-cell RNA sequencing (scRNA-seq) to analyze neutrophil heterogeneity in septic lungs and identified a distinct PD-L1 + neutrophil subpopulation. Using a murine model of sepsis induced by cecal ligation and puncture (CLP), we isolated PD-L1 RESULTS: scRNA-seq revealed a unique PD-L1 CONCLUSION: This study demonstrated that PD-L1 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-025-03412-5.
3. Individualized treatment rule for early steroid use in hospitalized patients with community acquired pneumonia: a cohort study.
In a single-center retrospective cohort (N=4,379), an individualized treatment rule for early steroids in CAP modestly increased 28-day hospital-free days versus observed practice (21.74 to 22.31) but showed inconsistent performance across outcomes. Overall, the ITR did not consistently improve clinical outcomes.
Impact: Demonstrates a rigorous individualized decision framework and highlights the challenges of translating algorithmic treatment selection into consistent clinical benefit.
Clinical Implications: Routine use of algorithm-guided early steroids in CAP is not supported without external validation; clinicians should apply steroids selectively based on clinical judgment and guidelines.
Key Findings
- An optimal LASSO-based ITR increased mean 28-day hospital-free days from 21.74 (95% CI 21.52–21.95) to 22.31 (95% CI 22.11–22.51) versus observed practice.
- Secondary outcomes (ventilator-free days, mortality, advanced respiratory failure support and/or mortality) showed better estimates with the ITR but lacked consistency across models.
- Among 4,379 hospitalized CAP patients, 32% received steroids within 24 hours of admission.
Methodological Strengths
- Large cohort with explicit primary outcome (28-day hospital-free days).
- Rigorous regression-based learning (LASSO) to individualize treatment recommendations and comparison against observed practice.
Limitations
- Single-center retrospective design with potential residual confounding.
- Lack of consistent benefit across outcomes limits clinical adoption.
- External validation was not reported.
Future Directions: Prospective external validation and randomized trials to test ITR-guided steroid strategies and to refine predictors for clinically meaningful endpoints.
BACKGROUND: Current evidence on an optimal patient selection strategy for adjunctive steroids to curb excessive inflammation in community acquired pneumonia (CAP) is limited. An individualized treatment rule (ITR) customizes treatment recommendations based on individual patient characteristics. The objective of this study was to develop an ITR for early steroid use in hospitalized patients with CAP. METHODS: Using a single center cohort of hospitalized patients with CAP from 2009 to 2019, we developed a single decision ITR to initiate or not initiate steroids early (within 24 h) after admission. The primary outcome of interest was hospital-free days measured at 28 days. Regression-based learning with LASSO selected a model estimating expected outcomes of potential intervention with steroids individualized to predictors. The optimal ITR was compared to other treatment rules including as observed in the data. RESULTS: A total of 4379 patients were included in this cohort with 1412 (32%) patients receiving steroids within 24 h of hospital admission. Compared to observed practice, an optimal ITR was associated with increased hospital-free days (mean rate [95% confidence interval (CI)]: 21.74 [21.52, 21.95] versus 22.31 [22.11, 22.51]). The optimal ITR for the secondary outcomes including ventilator-free days, mortality and need for advanced respiratory failure support and/or mortality revealed better estimates compared to what was observed in the data. However, there was a lack of consistent performance when applying the advanced respiratory failure and/or mortality (a secondary outcome) ITR to other outcomes (inconsistency of results across models). CONCLUSION: An ITR for early steroid use in hospitalized patients with CAP did not consistently improve clinical outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41479-025-00182-y.